Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection

Figure 1 Flow diagram of the enrollment process. NAs: Nucleos(t)ide analogues; HBV: Hepatitis B virus; CKD: Chronic kidney disease.

Figure 2 Cumulative incidence of end-stage renal disease after adjustment for competing mortality among (A) propensity score-matched chronic kidney disease cohort and (B) propensity score-matched hepatitis B virus cohort. ESRD: End-stage renal disease.

Figure 3 Stratified analyses after adjustment for competing mortality in the (A) propensity score-matched chronic kidney disease cohort and (B) propensity score-matched hepatitis B virus cohort. PY: person-year; ESRD: end-stage renal disease; HBV: Hepatitis B virus; CI: confidence interval. ¹Adjusted for all covariates (age per year, sex, comorbidities, geographic region, urbanization level, enrolee category, number of medical visits, Charlson comorbidity index score, and propensity score) and competing mortality, minus the covariate on which stratified.